TrialHuman vaccines & immunotherapeutics2014

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.

Shiro Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.